Organon & Co (OGN)
Gross profit margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | ||
---|---|---|---|---|---|---|---|---|---|---|
Gross profit (ttm) | US$ in thousands | 1,677,000 | 1,693,000 | 1,859,000 | 1,916,000 | 2,032,000 | 2,156,000 | 2,223,000 | 2,244,000 | 2,141,000 |
Revenue (ttm) | US$ in thousands | 6,263,000 | 6,150,000 | 6,168,000 | 6,145,000 | 6,174,000 | 6,292,000 | 6,355,000 | 6,365,000 | 6,304,000 |
Gross profit margin | 26.78% | 27.53% | 30.14% | 31.18% | 32.91% | 34.27% | 34.98% | 35.26% | 33.96% |
December 31, 2023 calculation
Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $1,677,000K ÷ $6,263,000K
= 26.78%
The gross profit margin of Organon & Co. has exhibited a declining trend over the past few quarters. From Q1 2022 to Q4 2023, the gross profit margin has decreased steadily from 63.05% to 59.84%. This indicates that the company's cost of goods sold relative to its revenue has been increasing, resulting in a lower percentage of revenue retained as gross profit. It is crucial for the company to closely monitor and potentially address the factors contributing to this decline in order to maintain healthy profitability levels.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Organon & Co
OGN
26.78%
Abbott Laboratories
ABT
20.40%
AbbVie Inc
ABBV
32.16%
Alkermes Plc
ALKS
29.02%
Amphastar P
AMPH
54.49%
ANI Pharmaceuticals Inc
ANIP
11.30%
Arcus Biosciences Inc
RCUS
-4.27%
Biomarin Pharmaceutical Inc
BMRN
78.98%
Bristol-Myers Squibb Company
BMY
37.48%
Catalent Inc
CTLT
21.82%
Catalyst Pharmaceuticals Inc
CPRX
49.46%